DTPA胃漂浮囊心缓释片制备与体外释放性能

Preparation and In Vitro Release of DTPA Intragastric Floating Sustained-Release and Capsule-Heart Tablets

采用粉末直接压片法制备二乙基三胺五乙酸(DTPA)胃漂浮囊心缓释片,并对其进行体外漂浮性能、释放性能和释药机理研究.结果表明:DTPA胃漂浮囊心缓释片在人工胃液中可以立即起漂,持续漂浮时间长达24h,其释药过程用Korsmeyer-Peppas(T_(lag))模型拟合的拟合度最好;同时,应用Harland方程进行验证,证明该制剂的释药过程主要为扩散和骨架溶蚀共同作用.通过该法制备的胃漂浮囊心缓释片具有起漂时间短、持续漂浮时间长、缓释效果好,漂浮性能不受制剂辅料和制备工艺的影响等优点.

Diethylene triamine pentaacetic acid（DTPA）intragastric floating sustained-release and capsuleheart tablets were prepared by pressing the powder directly,and the in vitro floatation,release characteristics and release mechanism were studied.Results indicated that DTPA intragastric floating sustained-release and capsule-heart tablets could float immediately in the simulated gastric fluid,floating up to 24 hours continuously,and the in vitro drug release with Korsmeyer-Peppas（T（lag））model fitting was the best.At the same time,it was proved that the drug release was controlled by diffusion and matrix erosion together using Harland equation for validation.In conclusion,intragastric floating sustained-release and capsule-heart tablets have the advantages of short floating lag time,long floating duration and good sustained-release effect.In addition,the floating characteristics were not affected by the excipients and the preparation technologies.